1-20 of 31
Huanling Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Li Weiming, Yanli Zhang, Huanling Zhu, Yunfan Yang, Na Xu, Bingcheng Liu, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu
Journal: Blood
Blood (2024) 144 (Supplement 1): 480.
https://doi.org/10.1182/blood-2024-204996
Published: 2024
Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Yi Zhang, Hu Zhou, Shanshan Suo, Junling Zhuang, Linhua Yang, Aili He, Qingchi Liu, Xin Du, Sujun Gao, Yarong Li, Yan Li, Yuqing Chen, Wen Wu, Huanling Zhu, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Hongmei Jing, Jishi Wang, Na Xu, Lingling Yue, Cuiping Zheng, ZePing Zhou, Chenghao Jin, Xin Li, Lin Liu, Yajing Xu, Dengshu Wu, Feng Zhang, Jin Zhang, Zhijian Xiao, Jie Jin
Journal: Blood
Blood (2024) 144 (Supplement 1): 3165.
https://doi.org/10.1182/blood-2024-202790
Published: 2024
Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Lu Yu, Huifang Wang, Xiaoli Liu, Bingcheng Liu, Xielan Zhao, Qun He, Qingshu Zeng, Zimin Sun, Ting Liu, Huanling Zhu, Zhuogang Liu, Xin Du, Jie Jin, Li Meng, Ming Hou, Suning Chen, Linhua Yang, Mingji Xian, Yoshitaka Kotobuki, Shuang Zhang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6602.
https://doi.org/10.1182/blood-2024-208258
Published: 2024
Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Xiaoshuai Zhang, Lu Yu, Li Zhou, Yanli Zhang, Huanling Zhu, Bingcheng Liu, Xin Du, Xiaodong Wang, Linhua Yang, Yanping Ma, Li Meng, Yanqing Zhang, Guohui Li, Lijie Yang, Baohong Wang, Xuehong Ran, Jian Huang, Qin Wen, Yan Wen, Yuxia Zhao, Yu Zhu, Yanqiu Han, Zhenfang Liu, Xin Du, Jianyu Weng, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4529.
https://doi.org/10.1182/blood-2024-203533
Published: 2024
Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4540.
https://doi.org/10.1182/blood-2024-202876
Published: 2024
Journal Articles

Effectiveness of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria in China: A Real World Study

He LI, Xinmei Yu, Juan Qiu, Lei Jia, Huanling Zhu, Ting Niu, Zhigang Liu, Chuan He
Journal: Blood
Blood (2024) 144 (Supplement 1): 5696.
https://doi.org/10.1182/blood-2024-212316
Published: 2024
Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical Trials & Observations
Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan, Yunfan Yang, Hai Lin, Xin Du, Rong Liang, Chunyan Chen, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li’e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (18): 1951–1961.
https://doi.org/10.1182/blood.2024024761
Published: 2024
Includes: Supplemental data
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3167.
https://doi.org/10.1182/blood-2023-185473
Published: 2023
Journal Articles

Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib

Yuntao Liu, Yunfan Yang, Hui Sun, Li Meng, Hai Lin, Chunyan Chen, Jianda Hu, Xuliang Shen, Minghui Duan, Yanli Zhang, Dilinazi Abulaiti, Jinghua Wang, Hongqian Zhu, Luoming Hua, Qing Leng, Chun Zhang, Lili Sun, Weiming Li, Huanling Zhu, Bingcheng Liu, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6367.
https://doi.org/10.1182/blood-2023-190780
Published: 2023
Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huanling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Shanshan Suo, Wenjuan Yu, Jie Jin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1814.
https://doi.org/10.1182/blood-2023-179043
Published: 2023
Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Sen Yang, Xiaoshuai Zhang, Yanli Zhang, Xin Du, Jianyu Weng, Huanling Zhu, Ling Pan, Yun-fan Yang, Li Meng, Zhenfang Liu, Xiaoli Liu, Na Xu, Chunyan Chen, Xiaodong WANG, Rong Liang, Jian Huang, Guohui Li, Chunshui Liu, Hai Lin, Jianda Hu, Li Fei, Bingcheng Liu, Weiming Li, Zhuogang Liu, Wei Yang, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 815–817.
https://doi.org/10.1182/blood-2022-166855
Published: 2022
Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3891–3894.
https://doi.org/10.1182/blood-2022-168812
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yunfan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9620–9623.
https://doi.org/10.1182/blood-2022-166431
Published: 2022
Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9637–9639.
https://doi.org/10.1182/blood-2022-168703
Published: 2022
Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio
Journal: Blood
Blood (2022) 140 (Supplement 1): 9647–9649.
https://doi.org/10.1182/blood-2022-164444
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Jiang Qian, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yongping Song, Gongli Zhang, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yujun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3598.
https://doi.org/10.1182/blood-2021-153937
Published: 2021
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020
Journal Articles

Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Ting Liu, MD, Huanling Zhu, MD, Xuekun Yao, M.M., Yueying Peng, M.M., Yumei Wang, M.E., Guoning Zhan, B.E., Jing Yuan, M.S., Shaonan Ni, M.M., Jie Qiao, PhD, Zijian Hu, MD, Cheng Lyu, D.Eng.
Journal: Blood
Blood (2019) 134 (Supplement_1): 2654.
https://doi.org/10.1182/blood-2019-128472
Published: 2019